<DOC>
	<DOCNO>NCT00086164</DOCNO>
	<brief_summary>The purpose study determine effect recipient vein pretreatment edifoligide ( E2F Decoy ) , compare placebo , graft/recipient vein stenosis polytetrafluoroethylene ( PTFE ) vascular access graft place hemodialysis 6 month enrollment .</brief_summary>
	<brief_title>Prevention Vascular Access Graft Failure Patients With Chronic Renal Failure Requiring Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Be schedule undergo placement new straight loop arm PTFE arteriovenous hemodialysis access graft Vectragraft® ( Thoratec , Inc. ) Be currently receive chronic dialysis expect begin hemodialysis within 4 week placement index PTFE graft Have undergo assessment patency ( venography ) central vein follow condition occur ipsilateral arm intend graft placement : presence collateral vein , upper extremity edema increase size ( relative contralateral arm ) , history subclavian catheter , transvenous pacemaker , history trauma surgery may involve neck chest vein Be &gt; 18 &lt; 80 year old Have document negative serum pregnancy test ( woman childbearing potential ) Be use acceptable method birth control reproductive potential agree continue use birth control least 3 month follow graft procedure Have agree participate voluntarily sign date IRB/EC approve , Patient Informed Consent form Have intend recipient vein &gt; 6 mm &lt; 3 mm diameter Have history three previous PTFE graft Have uncorrected central vein ( include subclavian vein ) stenosis Have markedly diminish arterial pulse access location ( unless adequate flow document arteriography Doppler ultrasound ) Anticipate receipt renal transplant within 6 month enrollment study Have anticipate use index PTFE graft &lt; 14 day enrollment ( apply Vectragraft® ) Have know allergy iodinate contrast Have know hypercoagulable state ( e.g. , antithrombin III deficiency ; antiphospholipid anticardiolipin antibody ; Factor V Leiden ; circulate lupus anticoagulant ; current , active , heparininduced thrombocytopenia ; Protein C S deficiency ; history recurrent deep venous thrombosis relate AV access ) Have another investigational ( i.e. , nonapproved ) drug device study within previous 30 day prior participation another clinical study E2F Decoy Have previously enrol study earlier access graft Have comorbid , nonrenal condition make 6month survival questionable ( e.g. , endstage cancer , advance heart failure ) Have know suspected history drug alcohol abuse within previous 6 month Have know allergy component investigational product ( drug device ) , include latex</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>edifoligide</keyword>
	<keyword>E2F Decoy</keyword>
	<keyword>Chronic Renal failure</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>AV Graft</keyword>
	<keyword>neointimal hyperplasia</keyword>
</DOC>